CA2442015A1 - Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese - Google Patents

Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese Download PDF

Info

Publication number
CA2442015A1
CA2442015A1 CA002442015A CA2442015A CA2442015A1 CA 2442015 A1 CA2442015 A1 CA 2442015A1 CA 002442015 A CA002442015 A CA 002442015A CA 2442015 A CA2442015 A CA 2442015A CA 2442015 A1 CA2442015 A1 CA 2442015A1
Authority
CA
Canada
Prior art keywords
tumor
angiogenesis
inhibitor
mek
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002442015A
Other languages
English (en)
Inventor
Nicholas S. Duesbery
Craig P. Webb
George F. Vandewoude
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Van Andel Research Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2442015A1 publication Critical patent/CA2442015A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode permettant d'inhiber l'angiogénèse cellulaire, consistant à mettre en contact des cellules associées à une angiogénèse non souhaitée avec une quantité efficace d'un inhibiteur de MEK ou d'une enzyme qui appartient à la famille MAPK. Les inhibiteurs MEK comprennent des protéases spécifiques de MEK, telles que le facteur létal Bacillus anthracis ou un dérivé fonctionnel de ce dernier. Des petits inhibiteurs moléculaires organiques de MEK comprennent PD98059, U0126 et PD184352. Cette mise en contact peut être réalisée in vivo, chez un patient humain ou chez un autre sujet mammifère. L'invention concerne également une méthode permettant de traiter un sujet mammifère présentant un trouble ou une affection associé à une angiogénèse non souhaitée ou à une néovascularisation, laquelle méthode consiste à administrer au sujet une quantité efficace d'une composition pharmaceutique comprenant un inhibiteur de MEK ou une enzyme appartenant à la famille MAPK susmentionnée, et un véhicule ou excipient pharmaceutiquement acceptable. La méthode thérapeutique peut être utile pour une maladie ou une affection, telle que la croissance tumorale, l'invasion tumorale ou la métastase tumorale, dans laquelle l'inhibition de l'angiogénèse se traduit par la réduction de la taille ou de la vitesse de croissance de la tumeur, ou encore, par sa destruction.
CA002442015A 2001-03-22 2002-03-22 Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese Abandoned CA2442015A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27762501P 2001-03-22 2001-03-22
US60/277,625 2001-03-22
PCT/US2002/008656 WO2002076496A1 (fr) 2001-03-22 2002-03-22 Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese

Publications (1)

Publication Number Publication Date
CA2442015A1 true CA2442015A1 (fr) 2002-10-03

Family

ID=23061685

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002442015A Abandoned CA2442015A1 (fr) 2001-03-22 2002-03-22 Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese

Country Status (4)

Country Link
EP (1) EP1377312A4 (fr)
AU (1) AU2002255852B2 (fr)
CA (1) CA2442015A1 (fr)
WO (1) WO2002076496A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1365796A2 (fr) * 2000-09-01 2003-12-03 Van Andel Institute Inhibition de la voie de la proteine mapkkk: une strategie therapeutique selective contre les melanomes
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20070116687A1 (en) * 2003-05-13 2007-05-24 Medvet Science Pty, Ltd. Method of modulating cellular transmigration and agents for use therein
EP1648493B1 (fr) * 2003-07-07 2009-12-09 Van Andel Research Institute Inhibition de l'angiogenese tumorale par combinaison de la thrombospondine-1 et des inhibiteurs du facteur de croissance endotheliale vasculaire
RU2352558C2 (ru) 2003-10-21 2009-04-20 Уорнер-Ламберт Компани Ллс Полиморфная форма n-[(r)-2,3-дигидроксипропокси]-3,4-дифтор-2-(2-фтор-4 йодфениламино)бензамида
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
AT504159A1 (de) 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc Verwendung von proteasen
WO2009132397A1 (fr) * 2008-05-01 2009-11-05 University Of South Australia Procédés et agents pour la modulation du taux et/ou de l'activité de la protéine hif-2 alpha
EP2701694A4 (fr) * 2011-04-28 2014-10-08 Univ Duke Procédés de traitement d'hémoglobinopathies
WO2013082511A1 (fr) * 2011-12-02 2013-06-06 Genentech, Inc. Procédés pour surmonter la résistance tumorale aux antagonistes de vegf
US9861685B2 (en) 2012-11-20 2018-01-09 Duke University Methods of treating hemoglobinopathies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405941A (en) * 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
GB2323845A (en) * 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
WO1999001426A1 (fr) * 1997-07-01 1999-01-14 Warner-Lambert Company Derives d'acide benzhydroxamique phenylamino 4-bromo ou 4-iodo et utilisation de ces derniers en tant qu'inhibiteurs de mek
CA2324379C (fr) * 1998-04-01 2012-12-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Le facteur letal de l'anthrax est une protease de type kinase
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
EE200100339A (et) * 1998-12-22 2002-10-15 Warner-Lambert Company Kombineeritud kemoteraapia
ES2251851T3 (es) * 1999-01-13 2006-05-01 Warner-Lambert Company Llc Acidos sulfohidroxamicos y sulfohidroxamatos y su uso com inhibidores mek.
US6545030B1 (en) * 1999-01-13 2003-04-08 Warner-Lambert Company 1-heterocycle substituted diarylamines
AU3631500A (en) * 1999-03-19 2000-10-09 Du Pont Pharmaceuticals Company N-adamant-1-yl-n'-(4-chlorobenzothiazol-2-yl) urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
AU3761400A (en) * 1999-03-19 2000-10-09 Du Pont Pharmaceuticals Company Amino-thio-acrylonitriles as mek inhibitors
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910580D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
AU2002255852B2 (en) 2006-11-09
WO2002076496A1 (fr) 2002-10-03
EP1377312A1 (fr) 2004-01-07
EP1377312A4 (fr) 2004-10-06

Similar Documents

Publication Publication Date Title
AU2002255852B2 (en) Anthrax lethal factor inhibits tumor growth and angiogenesis
Lamoreaux et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cellsin vitro
Gong et al. Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis
JP2023178440A (ja) ヌトリン３ａおよびペプチドを用いた肺線維症の阻害
Ntayi et al. Elastin-derived peptides upregulate matrix metalloproteinase-2-ediated melanoma cell invasion through elastin-binding protein
AU2002255852A1 (en) Anthrax lethal factor inhibits tumor growth and angiogenesis
Lyons III et al. The role of VEGF pathways in human physiologic and pathologic angiogenesis
US20040136975A1 (en) Anthrax lethal factor inhibits tumor growth and angiogenesis
Roncal et al. New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator
Beamish et al. Deciphering the relative roles of matrix metalloproteinase‐and plasmin‐mediated matrix degradation during capillary morphogenesis using engineered hydrogels
AU2007200573A1 (en) Anthrax lethal factor inhibits tumor growth and angiogenesis
JP2004503583A (ja) 癌の治療のための、マトリックス・メタロプロテアーゼ阻害剤の使用
AU2001288562B2 (en) Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma
Esser et al. Plasminogen in proliferative vitreoretinal disorders
Gualandris et al. Urokinase-type plasminogen activator overexpression enhances the invasive capacity of endothelial cells
Proia et al. The effect of endothelial cell overexpression of plasminogen activator inhibitor-1 on smooth muscle cell migration
US7537759B2 (en) Modulating angiogenesis
Beauregard et al. Nitric oxide and cyclic GMP-mediated protein secretion from cultured lacrimal gland acinar cells
WO2000067737A2 (fr) UTILISATION D'INHIBITEURS DE HMGCoA REDUCTASE POUR LA PREVENTION DE MALADIES DONT LA PATHOGENESE DEPEND D'UNE NEOFORMATION DE VAISSEAUX SANGUINS
Tsiamis Regulation and physiological role of the proteolytic cleavage of the endothelial receptor tyrosine kinsae TIE-1 in vessel destabilisation prior to angiogenesis
Proença Effects on migration of breast cancer cells in 3D models upon MMP inhibition
AU2002220098A1 (en) Modulating angiogenesis
Massaro‐Giordano et al. Plasminogen activator inhibitor type 2 (PAI‐2) is present in normal human conjunctiva
Wang The effect of hypoxia on the urokinase plasminogen activator system and cell adhesion and migration in human corneal epithelial cells
WO2000000192A1 (fr) INHIBITION DE LESIONS DES TISSUS INDUITES PAR NF-λB AU MOYEN DE DERIVES DE DITHIOCARBAMATE

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued